BioNTech SE (BNTX)
102.08
-9.32
(-8.37%)
USD |
NASDAQ |
Aug 28, 16:00
102.50
+0.42
(+0.42%)
Pre-Market: 20:00
BioNTech Cash from Operations (Quarterly) : 12.56M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.56M |
| March 31, 2026 | -492.54M |
| December 31, 2025 | 351.53M |
| September 30, 2025 | 854.07M |
| June 30, 2025 | 132.67M |
| March 31, 2025 | -821.66M |
| December 31, 2024 | -501.21M |
| September 30, 2024 | -687.85M |
| June 30, 2024 | 1.759B |
| March 31, 2024 | -344.38M |
| December 31, 2023 | 850.76M |
| September 30, 2023 | 898.37M |
| June 30, 2023 | 4.746B |
| Date | Value |
|---|---|
| March 31, 2023 | -726.81M |
| December 31, 2022 | 588.71M |
| September 30, 2022 | 4.844B |
| June 30, 2022 | 4.185B |
| March 31, 2022 | 4.544B |
| December 31, 2021 | -251.29M |
| September 30, 2021 | 1.800B |
| June 30, 2021 | -120.71M |
| March 31, 2021 | -374.96M |
| December 31, 2020 | 278.19M |
| September 30, 2020 | -216.61M |
| June 30, 2020 | -16.76M |
| March 31, 2020 | -60.25M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Moderna, Inc. | -526.00M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -2.571M |
| Mereo BioPharma Group Plc | -6.048M |
| MediGene AG | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -118.82M |
| Cash from Financing (Quarterly) | -126.88M |
| Free Cash Flow | 424.34M |
| Free Cash Flow Per Share (Quarterly) | -0.2077 |
| Free Cash Flow to Equity (Quarterly) | -64.68M |
| Free Cash Flow to Firm (Quarterly) | -48.28M |
| Free Cash Flow Yield | 1.68% |